IDNA ETF — Holdings & Analysis

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an equity ETF with $0.15 billion in assets under management.

Launched in 2019, IDNA provides targeted exposure to companies that could benefit from innovation in genomics, immunology, and bioengineering across developed and emerging markets. With an expense ratio of 0.47%, IDNA offers a focused approach to investing in the rapidly evolving healthcare landscape, differentiating itself through its emphasis on genomics and immunology-related companies.

iShares Genomics Immunology and Healthcare ETF (IDNA) ETF — Price, Holdings & Analysis

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an equity ETF with $0.15 billion in assets under management. Launched in 2019, IDNA provides targeted exposure to companies that could benefit from innovation in genomics, immunology, and bioengineering across developed and emerging markets. With an expense ratio of 0.47%, IDNA offers a focused approach to investing in the rapidly evolving healthcare landscape, differentiating itself through its emphasis on genomics and immunology-related companies.

ETF Overview

The iShares Genomics Immunology and Healthcare ETF seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.

IDNA aims to capture the growth potential of companies involved in genomics, immunology, and bioengineering. The ETF tracks an index composed of developed and emerging market companies believed to benefit from long-term growth and innovation in these fields. IDNA's portfolio consists of 52 holdings, with a significant allocation to the healthcare sector (97.5%). Top holdings include Moderna Inc (6.57%), Arcellx Inc (4.91%), and Ipsen SA (4.67%), reflecting a focus on innovative pharmaceutical and biotechnology companies. The fund's country exposure is heavily weighted towards the United States (60.5%), followed by France (8.6%) and Germany (7.3%). This targeted approach makes IDNA suitable for investors seeking specialized exposure to the genomics and immunology sub-sectors within the broader healthcare industry.

Risk Metrics

IDNA's concentrated sector allocation (97.5% in Healthcare) exposes it to sector-specific risks, meaning that the ETF's performance is highly dependent on the performance of the healthcare industry, particularly genomics and immunology companies. The ETF's beta of 1.35 (3-year) indicates that it is more volatile than the overall market. The fund's expense ratio of 0.47% will create a drag on returns, reducing overall performance by that amount annually. The fund's relatively small AUM of $0.15B could present liquidity risks, especially during periods of market stress. Investors should be aware of these factors when considering an investment in IDNA. Past performance does not guarantee future results.

Expense Ratio

0.47%

What does IDNA hold?

Holding	Weight
Moderna Inc (MRNA)	6.57%
Arcellx Inc (ACLX)	4.91%
Ipsen SA (IPN.PA)	4.67%
Takeda Pharmaceutical Co Ltd (4502.T)	4.46%
Revolution Medicines Inc Ordinary Shares (RVMD)	4.35%
Bayer AG (BAYN.DE)	4.35%
Merck & Co Inc (MRK)	4.22%
Roche Holding AG (ROG.SW)	4.20%
GSK PLC (GSK.L)	4.18%
BioNTech SE ADR (BNTX)	3.89%

How Is the Fund Allocated?

Sector	Weight
Healthcare	97.5%
Cash & Others	1.7%
Industrials	0.8%

Country	Weight
United States	60.5%
France	8.6%
Germany	7.3%
Japan	6.4%
Switzerland	5.6%
United Kingdom	4.1%
Denmark	3.1%
China	2.1%
Canada	0.9%
South Korea	0.8%

Dividend Yield

0.99%

State Street Technology Select Sector SPDR ETF (XLK) — 0.08% expense ratio
State Street Energy Select Sector SPDR ETF (XLE) — 0.08% expense ratio
Invesco QQQ Trust, Series 1 (QQQ) — 0.18% expense ratio
State Street SPDR Dow Jones Industrial Average ETF Trust (DIA) — 0.16% expense ratio
iShares Russell 2000 ETF (IWM) — 0.19% expense ratio
State Street Financial Select Sector SPDR ETF (XLF) — 0.08% expense ratio
iShares MSCI Emerging Markets ETF (EEM) — 0.72% expense ratio
iShares MSCI EAFE ETF (EFA) — 0.32% expense ratio

iShares Russell 2000 ETF (IWM) (Equity) — 0.19% expense ratio
iShares MSCI Emerging Markets ETF (EEM) (Equity) — 0.72% expense ratio
iShares MSCI EAFE ETF (EFA) (Equity) — 0.32% expense ratio
iShares FinTech Active ETF (BPAY) (Equity) — 0.66% expense ratio
iShares Blockchain and Tech ETF (IBLC) (Equity) — 0.47% expense ratio
iShares MSCI USA Momentum Factor ETF (MTUM) (Equity) — 0.15% expense ratio

Risk Metrics

Beta: 1.35

Questions & Answers

What is IDNA and what does it track?

The iShares Genomics Immunology and Healthcare ETF (IDNA) seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.

What is the expense ratio for IDNA?

The expense ratio for IDNA is 0.47%. This means that for every $10,000 invested in the ETF, $47 is deducted annually to cover the fund's operating expenses.

While this is a cost to consider, it's important to weigh it against the potential benefits of the ETF's focused investment strategy.

What are the top holdings in IDNA?

As of 2026-03-15, the top holdings in IDNA are Moderna Inc (6.57%), Arcellx Inc (4.91%), and Ipsen SA (4.67%). These companies represent a significant portion of the ETF's portfolio, reflecting its investment strategy focused on genomics, immunology, and healthcare.

The fund also holds Takeda Pharmaceutical Co Ltd (4.46%) and Revolution Medicines Inc Ordinary Shares (4.35%) among its top allocations.

Is IDNA a good long-term investment?

Whether IDNA is a suitable long-term investment depends on an individual's investment goals, risk tolerance, and time horizon. IDNA offers targeted exposure to the genomics, immunology, and healthcare sectors, which may experience growth due to technological advancements and demographic trends.

However, the ETF's concentration in these sectors also exposes it to sector-specific risks.

How does IDNA compare to similar ETFs?

IDNA differentiates itself through its specific focus on genomics, immunology, and healthcare. While other healthcare ETFs may offer broader exposure to the healthcare sector, IDNA targets companies involved in these specific sub-sectors.

The fund's expense ratio is 0.47%, which is comparable to other specialized healthcare ETFs.

Does IDNA pay dividends?

Yes, IDNA does pay dividends. The current dividend yield for IDNA is 0.99%. This means that for every $100 invested in the ETF, investors can expect to receive $0.99 in dividend payments annually.

It's important to note that dividend yields can fluctuate over time due to changes in the ETF's underlying holdings and market conditions.